Scroll

methylergometrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
ergot alkaloid derivatives	1764	113-42-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methylergometrine maleate methylergonovine methergine methergen methylergobasin methylergobasine methylergobrevin partergin methylergonovine maleate methylergometrine methylergometrin	A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed) Molecular weight: 339.44 Formula: C20H25N3O2 CLOGP: 1.76 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 68.36 ALOGS: -3.22 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methylergometrine maleate
methylergonovine
methergine
methergen
methylergobasin
methylergobasine
methylergobrevin
partergin
methylergonovine maleate
methylergometrine
methylergometrin

A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)

Molecular weight: 339.44
Formula: C20H25N3O2
CLOGP: 1.76
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 68.36
ALOGS: -3.22
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	mg	O
0.20	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	7.18 mL/min/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	11.39 mg/mL	Bocci G, Oprea TI, Benet LZ
t_half (Half-life)	1.85 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.96 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 6 of 6 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Nov. 19, 1946	FDA	EDISON THERAPS LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	70.01	37.71	17	1050	6124	63481831
Postpartum haemorrhage	41.47	37.71	9	1058	1972	63485983
Cyanosis	40.91	37.71	14	1053	16921	63471034
Disseminated intravascular coagulation	39.30	37.71	14	1053	19037	63468918
Exposure during pregnancy	38.94	37.71	27	1040	155520	63332435

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	205.09	97.49	33	143	5301	34951454

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wrong product administered	145.52	134.14	27	100	9	89656

Showing 1 to 1 of 1 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	G02AB01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids
ATC	G02AC01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination
CHEBI has role	CHEBI:176497	geroprotectors
FDA CS	M0007652	Ergolines
FDA EPC	N0000175827	Ergot Derivative
MeSH PA	D010120	Oxytocics
MeSH PA	D012102	Reproductive Control Agents

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Postpartum hemorrhage	indication	47821001
Postabortal Hemorrhage	indication
Incomplete miscarriage	off-label use	156072005
Hypertensive disorder	contraindication	38341003	DOID:10763
Pregnancy-induced hypertension	contraindication	48194001
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Sepsis syndrome	contraindication	238150007

Showing 1 to 10 of 12 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.56	acidic
pKa2	13.6	acidic
pKa3	7.01	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	ANTAGONIST	Ki	6.27	DRUG MATRIX	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.56	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.23	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	8.63	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	AGONIST	Ki	9.40	IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	PARTIAL AGONIST	Ki	9.10	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	AGONIST	Ki	8.30	IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	8.93	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.68	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.24	DRUG MATRIX

Showing 1 to 10 of 17 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
H8D	PDB_CHEM_ID
001306	NDDF
004941	NDDF
126074008	SNOMEDCT_US
126075009	SNOMEDCT_US
150	IUPHAR_LIGAND_ID
160889	MMSL
227555	RXNORM
2900	INN_ID
4018757	VUID

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
METHERGINE	HUMAN PRESCRIPTION DRUG LABEL	1	12634-179	TABLET, COATED	0.20 mg	ORAL	NDA	21 sections
Methergine	HUMAN PRESCRIPTION DRUG LABEL	1	27437-050	TABLET	0.20 mg	ORAL	ANDA	18 sections
Methergine	HUMAN PRESCRIPTION DRUG LABEL	1	66336-402	TABLET, COATED	0.20 mg	ORAL	NDA	22 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0639	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0639	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3655	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0740	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	21 sections
Methylergonovine Maleate	Human Prescription Drug Label	1	16571-735	TABLET	0.20 mg	ORAL	ANDA	20 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-501	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections
Methylergonovine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-501	INJECTION	0.20 mg	INTRAVENOUS	ANDA	21 sections

Showing 1 to 10 of 24 entries

Previous1 2 3Next